You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

 

170 Results
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Funding:
Exceptional Access Program
    niLOtinib - Chronic phase Ph+ CML, with specific criteria
Exceptional Access Program
    niLOtinib - Accelerated phase Ph+ CML with documented resistance or intolerance to imatinib therapy, with specific criteria
Mar 2023
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Palliative
Funding:
Exceptional Access Program
    encorafenib - In combination with cetuximab or panitumumab in previously treated BRAF V600E-mutated metastatic colorectal cancer, according to clinical criteria
New Drug Funding Program
    Cetuximab - In Combination with Encorafenib for Previously Treated Metastatic Colorectal Cancer
Apr 2024
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
Exceptional Access Program
    SUNItinib - Metastatic renal cell carcinoma, with specific criteria
Oct 2020
Drug
Other Name(s): Zydelig™
Feb 2022
Drug
Other Name(s): Alunbrig®
Oct 2022
Drug
Other Name(s): Sprycel®
Oct 2022
Drug
Other Name(s): Nubeqa®
Mar 2024
Drug
Other Name(s): Zejula
Oct 2023
Drug
Other Name(s): Ibrance™
May 2021
Drug
Other Name(s): Onureg®
Aug 2023
Drug
Other Name(s): Inrebic®
May 2023
Drug
Other Name(s): Erleada®
Apr 2024

Pages